Original Contribution

Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs

Simopekka Vänskä*, Tapio Luostarinen, Camilla Lagheden, Carina Eklund, Sara Nordqvist Kleppe, Bengt Andrae, Pär Sparén, Karin Sundström, Matti Lehtinen, and Joakim Dillner

*Correspondence to Dr. Simopekka Vänskä, Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland (e-mail: simopekka.vanska@thl.fi).

Initially submitted November 27, 2019; accepted for publication May 4, 2020.

The elimination of cervical cancer rests on high efficacy of human papillomavirus (HPV) vaccines. The HPV type distribution among cases of invasive cervical cancer (ICC) is used to make predictions about the impact of eliminating different types of HPV, but accumulating evidence of differences in age-specific cancer incidence by HPV type exists. We used one of the largest population-based series of HPV genotyping of ICCs (n = 2,850; Sweden, 2002–2011) to estimate age-specific ICC incidence by HPV type and obtain estimates of the cancer-protective impact of the removal of different HPV types. In the base case, the age-specific ICC incidence had 2 peaks, and the standardized lifetime risk (SLTR, the lifetime number of cases per birth cohort of 100,000 females) for HPV-positive ICC was 651 per 100,000 female births. In the absence of vaccine types HPV 16 and HPV 18, the SLTR for ICC was reduced to 157 per 100,000 female births (24% of HPV-positive SLTR). Elimination of all 9 types that can currently be vaccinated against reduced the remaining SLTR to 47 per 100,000 female births (7%), the remaining ICC incidence only slowly increasing with age. In conclusion, after elimination of vaccine-protected HPV types, very few cases of ICC will be left, especially among fertile, reproductive-age women.

age-specific cervical cancer incidence; cervical cancer; disease eradication; HPV vaccine; human papillomavirus; vaccination

Abbreviations: HPV, human papillomavirus; ICC, invasive cervical cancer; SLTR, standardized lifetime risk.

Editor’s note: An invited commentary on this article appears on page 515.

Human papillomavirus (HPV) infection is virtually necessary for development of invasive cervical cancer (ICC) (1). Thirteen types of HPV have been established to be oncogenic, high-risk types, but a number of other mucosal types are also known to infect the genital tract (2). The incidence of ICC varies widely between populations, reflecting differences in both risk factors and cervical cancer screening policies (3).

There are 3 licensed prophylactic HPV vaccines that provide protection against HPV infection and its consequences, all based on virus-like particles. The quadrivalent vaccine is constructed using virus-like particles specific to HPV types 6, 11, 16, and 18; the bivalent vaccine is specific to types 16 and 18; and the nonavalent vaccine is specific to types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The vaccines are highly effective against infection with their respective HPV types (4–6). In addition, cross-protective efficacy has been demonstrated against HPV 31 for the quadrivalent vaccine and against HPVs 31, 33, 35, and 45 for the bivalent vaccine (7–9). Modeling studies predict that elimination of vaccine-protected HPV types from a vaccinated population is an achievable goal (10).

The HPV type distribution in ICC has been extensively studied. In a retrospective study (11) in which nearly 9,000...
specimens were collected worldwide and analyzed for HPV. HPV 16 was the most common type, with 61% presence in ICCs, followed by HPV 18 (10%) and HPV 45 (6%). In a systematic review, Bzhalava et al. (12) found the corresponding proportions to be 56%, 14%, and 5%. However, an age-specific baseline HPV type distribution in ICC is needed to predict and monitor the public health benefits of vaccination programs accurately. For example, if nonvaccine HPV types are particularly common in ICCs of certain age groups, that would imply differences between age groups in the cancer-protective effectiveness of vaccination programs. Data on age-specific ICC incidence by HPV type have been collected from the prevaccination era and suggest differences between HPV types (13, 14). However, a very large data set is required to achieve adequate age-specific accuracy in ICC incidence by HPV type. Moreover, the requirement is difficult to fulfill by combining smaller data sets from different populations, because disentangling the between-type differences from the impacts of different risk factors and screening policies would then be a challenge.

Here we present estimates of the age-specific incidence of ICC by HPV type based on a very large, population-based series of HPV genotyping of ICCs carried out during a 10-year period (15). Moreover, to reveal the ultimate potential of successful HPV vaccination programs, eliminating vaccine-protected types, it is necessary to advance our perspective from existing ICC incidence to the incidence that would remain in the absence of vaccine-protected HPV types.

**METHODS**

**Data**

Details of this study have been previously published (15). Briefly, all invasive cervical carcinomas diagnosed in Sweden in 2002–2011 were retrieved from the Swedish Cancer Registry. A senior gynecologist (B.A.) reviewed the medical records of the cases to confirm primary, invasive, epithelial tumors of cervical origin—thus ruling out, for instance, noninvasive lesions (e.g., cervical intraepithelial neoplasia grade 3, adenocarcinoma in situ), sarcomas, metastases from other locations, and recurrences. All 4,253 confirmed ICC cases (i.e., squamous cell carcinomas, adenocarcinomas, and other rare carcinomas) were included in the analysis and linked to the register data on age and date at diagnosis and county (1 duplicate case was previously interpreted in a different way (15)). The number of woman-years for the Swedish female population in 2002–2011 was obtained from Statistics Sweden.

Diagnostic slides and formalin-fixed paraffin-embedded blocks of confirmed ICC cases were requested from local pathology laboratories. A senior pathologist reviewed the diagnostic slides to reconfirm the cases and to choose the block with the greatest ratio of tumor tissue to healthy tissue for sectioning. For contamination control, a blank block was sectioned in-between each case block. The first and last sections were put on slides and stained using hematoxylin and eosin. DNA was extracted by a validated method using a Qiagen kit (QIAGEN N.V., Venlo, the Netherlands) with an extra heating step (16, 17). All samples were tested for both β-globin (to ensure the presence of human DNA) using real-time polymerase chain reaction and HPV type using modified general primer polymerase chain reaction (18) with primer target L1 and subsequent hybridization with HPV type-specific probes using Luminex (BioRad Laboratories B.V., Veenendaal, the Netherlands) (19). The cases with β-globin-negative results or with β-globin-positive blank blocks, indicating contamination, were excluded from HPV analyses. With Luminex, the HPV typing of each sample was determined for 13 high-risk HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and a number of low-risk HPV types (types 6, 11, 26, 30, 40, 42, 43, 53, 54, 61, 66, 67, 69, 70, 73, 74, 81, 82, 83, 86, 87, 89, 90, and 91). In addition, the slides from sectioning, first and last, of the HPV-negative samples were rereviewed by the pathologist to confirm invasive tumor tissue in the tested sections. HPV-negative samples were further evaluated with real-time polymerase chain reaction for HPV 16 and HPV 18, targeting primers E7 and E6, respectively.

Valid HPV genotyping results were obtained for 2,850 cases. Of the 1,403 cases without HPV results, 639 cases were from 5 biobank archives that did not send their blocks for this study at all; 706 cases were from the other 20 biobanks which agreed to the study but may not have had sufficient tumor material available; and 58 cases had blocks that were excluded from the HPV analyses.

The nationwide HPV genotyping study was approved by the Regional Ethical Review Board in Stockholm, which determined that because of the population-based nature of the study, informed consent from the study participants was not required and collection of the samples for histology review and HPV typing was permitted.

**Measures for HPV incidence**

All age-specific measures were estimated in 5-year age groups ($j = 5, 5–9, 10–14, 15–19, \ldots, 80–84, 85$ years). In age group $j$, the ICC incidence was estimated by $n(j)/N(j)$, where $n(j)$ is the number of ICC cases and $N(j)$ is the total number of woman-years, defined as 10 times the mean population in 2002–2011 within $j$. When estimating the type-specific incidence ($inc(j,t)$) in an age group $j$ for HPV type $t$ or grouped types $t$, we took into consideration that some ICC cases were without HPV results: We first estimated the proportion $pos(j,t)/k(j)$ of positive cases ($pos(j,t)$) for HPV type(s) $t$ among cases with known HPV results ($k(j)$) and then attributed that proportion of ICC incidence to type(s) $t$ to get

$$inc(j,t) = \frac{pos(j,t)}{k(j)} \times \frac{n(j)}{N(j)}$$

When estimating the statistics for the type-specific incidence $inc(j,t)$, we assumed that the proportion and the ICC incidence were mutually independent (see the Web Appendix, available at https://doi.org/10.1093/aje/kwa121).
As an age-standardized measure, we used the standardized lifetime risk (SLTR) \(20\) per 100,000 female births adjusted to the Swedish 2002–2011 female life tables \(21\). The SLTR per 100,000 female births equals the number of cases that would occur in a birth cohort of 100,000 females during their entire lifetime. In addition, for comparison purposes, we calculated the age-standardized incidence rates per 100,000 woman-years for the Swedish life-tables–based population and for the world (Segi 1960) \(22\) and European (1976) \(23\) standard populations (Web Table 1). Compared with the traditional standard population-based measures, the life-table–based measures are favorable for long-term predictions of HPV vaccination. The standard populations reflect current populations, so they are more applicable for instantaneous comparisons. If a standard population is translated to a cohort, the corresponding mortality will be much higher than it currently is in Sweden and many other developed countries. In particular, the European standard population \(24\) from 2013 is not applicable for long-term predictions, because middle-aged groups are even larger than some younger age groups.

The measures were computed for individual HPV types and for any HPV, high-risk HPV, low-risk HPV, and HPV negativity. In addition, we studied the following groups of HPV types based on the available vaccines: HPV 16/18, HPV 16/18/31, HPV 16/18/45, HPV 6/11/16/18, HPV 6/11/16/18/31, HPV 16/18/31/33/35/45, and HPV 6/11/16/18/31/33/35/45/52/58, both for those type(s) alone and allowing for the presence of other HPV types. To demonstrate the impacts of potential elimination of a group of types, we estimated the remaining HPV-positive ICC incidence in the absence of these types—that is, group \(t\) in the above incidence formula consisted of the HPV types other than the listed types. Thus, a case with multiple HPV types remained if any HPV type remained, even if usually the classification of the remaining type was less oncogenic; this made the estimates conservative.

**RESULTS**

There were 4,253 confirmed ICC cases after 46 million woman-years of follow-up in Sweden in 2002–2011 (Table 1, Web Tables 2 and 3). HPV results were available for 2,850 ICC cases, of which 2,456 were HPV-positive. Figure 1 presents the distribution of ICC cases by age group and availability of HPV results. The proportion of cases without HPV results varied only slightly between different age groups (28%–35% above age 30 years), with no clear trend.

Age-specific ICC incidence had 2 peaks, the first at ages 30–45 years, after which the incidence decreased for 10–20 years, and the second at older ages (approximately 70–80 years) (Figure 2A, Web Table 4). The much lower HPV-negative and low-risk HPV-positive ICC incidence curves had different shapes and increased slowly with age. Among type-specific incidences, HPV 16 alone clearly had 2 peaks (Figure 2B, Web Tables 5 and 6). The next 2 most common types, HPV 18 and HPV 45, had only 1 wide peak, and the incidence decreased thereafter with age. The incidences of the other single HPV types were more occasional, mostly increasing slightly toward older ages.

The SLTR for all ICC was 759 per 100,000 female births using the Swedish 2002–2011 life tables (Table 2, Web Table 1). Age-standardized ICC incidence rates were 9.1, 6.6, and 8.2 per 100,000 woman-years using the Swedish population, the world population, and the European standard population, respectively—the difference originating mainly from a varying proportion of older women.

The SLTR for HPV-positive ICC was 651 per 100,000 female births, of which 630 per 100,000 (97% of HPV-positive SLTR) were attributable to high-risk HPVs (Table 2). In the absence of high-risk HPV types, the SLTR for low-risk HPV ICC was only 21 per 100,000 female births (3.2% of HPV-positive SLTR). The SLTR for HPV-negative ICC was 109 per 100,000 female births (14% of all ICC SLTR).

The SLTR for vaccine types HPV 16- and 18-positive ICC was 509 per 100,000 female births, with a 78% proportion of HPV-positive SLTR being attributable to those 2 types (Table 2, Figure 3). Without HPV 16/18, the remaining HPV-positive SLTR was 157 per 100,000 female births (24% of baseline HPV-positive SLTR). With additional inclusion of a single cross-protective type, HPV 31, in the analysis, the SLTR for HPV 16/18/31-positive ICC increased to 529 per 100,000 female births (81%), and without these types the remaining HPV-positive SLTR decreased to 137 per 100,000 (21%). These numbers were close to the results for HPV 6/11/16/18/31: an SLTR of 534 per 100,000 female births (82%) for the attribution and an SLTR of 130 per 100,000 (20%) for the remainder. In contrast, inclusion of a single cross-protective type, HPV 45, resulted in stronger changes, with an SLTR of 555 per 100,000 female births (85%) for HPV 16/18/45 and an SLTR of 109 per 100,000 (17%) for the remaining HPV-positive ICCs. For HPV 16/18/31/33/35/45, the attribution was SLTR 594 per 100,000 female births (91%) and SLTR 69 per 100,000 (11%) for the remainder; and numbers were improved still further for HPV 6/11/16/18/31/33/35/45/52/58: up to SLTR 610 per 100,000 (94%) for the attribution and down to SLTR 47 per 100,000 (7%) for the remainder.

### Table 1. Human Papillomavirus Characteristics of Invasive Cervical Cancer Cases \((n = 4,253)\), Sweden, 2002–2011

| HPV Characteristic | No. of Cases | Proportion |
|--------------------|--------------|------------|
| Known              | 2,850        | 67.0       | 65.6, 68.4 |
| Unknown            | 1,403        | 33.0       | 31.6, 34.4 |
| HPV result         |              |            |            |
| Positive           | 2,456        | 86.2       | 84.9, 87.4 |
| Negative           | 394          | 13.8       | 12.6, 15.1 |

Abbreviations: CI, confidence interval; HPV, human papillomavirus.

\(a\) 46.1 million woman-years of follow-up.
Figure 4 presents the remaining age-specific incidences of HPV-positive ICC in the absence of different vaccine-protected groups of HPV types. The first of the 2 peaks in the baseline ICC incidence curve practically disappeared from the remaining incidences. After elimination of HPV 16/18 and HPV 6/11/16/18/31 and, respectively, HPV 16/18/31/33/35/45 and HPV 6/11/16/18/31/33/45/52/58, the curves were close to each other.

Because some ICC cases were HPV-negative, the proportions of HPV group-associated SLTRs were lower among all ICCs than HPV-positive SLTRs (Table 2).

**DISCUSSION**

In this paper, we have presented estimates of age-specific ICC incidence attributed to different types of HPV, particularly in the absence of vaccine-protected HPV types. The estimates made without vaccine-protected HPV types correspond to the situation that would exist after elimination of these types. The age-specific ICC incidences for vaccine-protected HPV types peaked strongly in fertile, reproductive-age women when compared with the other HPV types. As a consequence, the cancer-protective effectiveness of the removal of the vaccine-protected HPV
Table 2.  Standardized Lifetime Risk of Invasive Cervical Cancer (per 100,000 Female Births) and Age-Standardized Incidence Rates of Invasive Cervical Cancer (per 100,000 Woman-Years) Associated With Groups of Human Papillomavirus Types and, in the Absence of Those Types, by Group of Human Papillomavirus Types, Sweden, 2002–2011

| HPV Type(s)                          | SLTR per 100,000 Female Births (Sweden 2002–2011c) | Age-Standardized Incidence Rate per 100,000 Woman-Years |
|-------------------------------------|-------------------------------------------------|------------------------------------------------------|
|                                     | SLTR 95% CI | Proportion of ICC SLTRa | Proportion of HPV-Positive SLTRb | ASIR 95% CI | ASIR 95% CI | ASIR 95% CI |
| All ICC                             | 759 736,782 | 100.0 |                                | 9.1 8.8,9.4 | 8.2 79,8.4 | 6.6 6.4,6.8 |
| HPV-positive ICC                     | 651 629,673 | 85.7 81.8 89,95 |                                | 7.8 7.5,8.1 | 7.2 70,75 | 5.9 5.7,6.1 |
| HPV-negative ICC                     | 109 98,119  | 14.3 12.9 15,8  |                                | 1.3 12,14 | 1.0 9.9,11 | 0.7 0.6,0,8 |
| High-risk HPV types (any)⁷          | 630 608,652 | 82.9 79.1,86,7 | 96.8 92.1,100.0 | 7.6 73,78 | 7.1 6.8,73 | 5.8 5.6,6.0 |
| Only those types³                   | 621 600,643 | 81.8 78.0,85,6 | 95.5 90.9,99,4 | 7.5 72,77 | 7.0 6.7,72 | 5.7 5.5,5,9 |
| Remaining HPV-positive ICC⁵         | 29 24,35  | 3.9 3.1,4,7 | 4.5 3.6,5,4 | 0.4 0.3,0,4 | 0.2 0.2,0,3 | 0.2 0.1,0,2 |
| Low-risk HPV types (any)⁸           | 29 24,35 | 3.9 3.1,4,7 | 4.5 3.6,5,4 | 0.4 0.3,0,4 | 0.2 0.2,0,3 | 0.2 0.1,0,2 |
| Only those types³                   | 21 16,26  | 2.8 2.1,3,4 | 3.2 2.5,4,0 | 0.3 0.2,0,3 | 0.1 0.1,2 | 0.1 0.1,0,1 |
| Remaining HPV-positive ICC³         | 630 608,652 | 82.9 79.1,86,7 | 96.8 92.1,100.0 | 7.6 73,78 | 7.1 6.8,73 | 5.8 5.6,6.0 |
| Type 16 (any)⁷                     | 389 370,407 | 51.2 48.3,54,1 | 59.7 56.3,63,2 | 4.7 4.4,4,9 | 4.4 4.2,4,6 | 3.6 3.4,3,8 |
| Only those types³                   | 370 352,388 | 48.8 46.0,51,5 | 56.9 53.6,60,2 | 4.4 4.2,4,7 | 4.1 3.9,4,4 | 3.4 3.2,3,6 |
| Remaining HPV-positive ICC³         | 281 265,297 | 36.9 34.6,39,3 | 43.1 40.3,46,0 | 3.4 3.2,3,6 | 3.1 2.9,3,2 | 2.5 2.3,2,6 |
| Type 16 or 18 (any)⁸               | 509 489,529 | 67.0 63.7,70,4 | 78.2 74,2,82,3 | 6.1 5.9,6,3 | 5.9 5.6,6,1 | 4.9 4.7,5,1 |
| Only those types³                   | 494 474,514 | 65.1 618,68,4 | 75.9 72,0,79,9 | 5.9 5.7,6,2 | 5.7 5.5,5,9 | 4.7 4.5,4,9 |
| Remaining HPV-positive ICC³         | 157 144,169 | 20.6 18.9,22,4 | 24.1 22,0,26,2 | 1.9 17,20 | 1.5 14,16 | 1.2 1.1,1,3 |
| Type 16, 18, or 31 (any)⁹          | 529 508,549 | 69.6 66,2,73,0 | 81.2 77,1,85,3 | 6.3 6,1,6,6 | 6.0 5,8,6,3 | 5.0 4,8,5,2 |
| Only those types³                   | 514 494,534 | 67.7 64,4,71,1 | 79.0 74,9,83,1 | 6.2 5,9,6,4 | 5.9 5,7,6,1 | 4.9 4,7,5,1 |
| Remaining HPV-positive ICC³         | 137 125,148 | 18.0 16,4,19,6 | 21.0 19,1,22,9 | 1.6 15,1,8 | 1.3 12,1,4 | 1.0 0,9,1,1 |
| Type 16, 18, or 45 (any)⁹          | 555 534,576 | 73.1 69,6,76,6 | 85.3 81,0,89,5 | 6.7 6,4,6,9 | 6.4 6,2,6,7 | 5,3 5,1,5,5 |
| Only those types³                   | 541 521,562 | 71.3 67,9,74,8 | 83.2 790,87,4 | 6.5 6,3,6,7 | 6,3 6,0,6,5 | 5,2 5,0,5,4 |
| Remaining HPV-positive ICC³         | 109 99,120 | 14.4 12,9,15,9 | 16.8 15,1,18,5 | 1.3 12,1,4 | 0.9 0,8,1,0 | 0.7 0.6,0,8 |
| Type 6, 11, 16, 18, or 31 (any)⁹  | 534 514,555 | 70.4 66,9,73,8 | 82.1 779,86,3 | 6.4 6,2,6,7 | 6,1 5,9,6,3 | 5,0 4,8,5,2 |
| Only those types³                   | 521 501,541 | 68.6 652,72,0 | 80,1 75,9,84,2 | 6.3 6,0,6,5 | 5.9 5,7,6,2 | 4.9 4.7,5,1 |
| Remaining HPV-positive ICC³         | 130 118,141 | 17.1 15,5,18,7 | 19,9 18,1,21,8 | 1.6 14,1,7 | 1.3 11,1,4 | 1.0 0,9,1,1 |
| Type 16, 18, 31, 33, 35, or 45 (any)⁹ | 594 573,615 | 78.2 74,5,81,9 | 91.3 86,8,95,5 | 7.1 6,9,7,4 | 6.7 6,5,7,0 | 5.5 5,3,5,8 |
| Only those types³                   | 581 560,602 | 76.6 72,9,80,2 | 89,3 849,93,6 | 7.0 6,7,7,2 | 6,6 6,4,6,8 | 5,4 5,2,5,6 |
| Remaining HPV-positive ICC³         | 69 61,78 | 9.1 8,0,10,3 | 10.7 9.3,12,0 | 0.8 0.7,0,9 | 0.6 0.5,0,7 | 0.5 0,4,0,5 |
### Table 2. Continued

| HPV Type(s) | SLTR per 100,000 Female Births (Sweden 2002–2011<sup>c</sup>) | Age-Standardized Incidence Rate per 100,000 Woman-Years |
|-------------|-------------------------------------------------------------|-------------------------------------------------------|
|             | SLTR            | Proportion of ICC | Proportion of HPV-Positive SLTR | Sweden 2002–2011<sup>c</sup> | ASIR            | 95% CI | ASIR            | 95% CI | ASIR            | 95% CI |
|             | SLTR<sup>a</sup> | %                | 95% CI | %                | 95% CI | %                | 95% CI |
| Type 6, 11, 16, 18, 31, 33, 45, 52, or 58 (any)<sup>f</sup> | 610 | 580, 632 | 80.4 | 76.6, 84.1 | 93.6 | 87.8, 98.2 | 94.5 | 71.7, 96.0 | 65.6 | 42.4, 87.1 |
| Only those types<sup>g</sup> | 604 | 583, 625 | 79.5 | 75.8, 83.2 | 92.6 | 88.2, 97.0 | 73.2 | 70.7, 75.7 | 66.6 | 62.5, 71.0 |
| Remaining HPV-positive ICC<sup>h</sup> | 47 | 40, 54 | 6.2 | 5.2, 7.1 | 7.2 | 6.1, 8.3 | 0.6 | 0.5, 0.6 | 0.4 | 0.3, 0.5 |

Abbreviations: ASIR, age-standardized incidence rate; CI, confidence interval; HPV, human papillomavirus; ICC, invasive cervical cancer; SLTR, standardized lifetime risk.

<sup>a</sup> SLTR per all ICC SLTR (759 per 100,000 female births).

<sup>b</sup> SLTR per HPV-positive SLTR (651 per 100,000 female births).

<sup>c</sup> ASIR for the Swedish 2002–2011 female life-tables–based population.

<sup>d</sup> ASIR for the European 1976 standard population (23).

<sup>e</sup> ASIR for the world standard population (22).

<sup>f</sup> ICC positive for any HPV type in the group (other HPV types allowed).

<sup>g</sup> ICC positive for any HPV type in that group only (negative for all other HPV types).

<sup>h</sup> ICC positive for HPV but negative for all HPV types in that group.
Mathematical modeling studies provide timelines for how fast our register-based observations about ICC incidences without vaccine-protected HPV types could be realized under HPV vaccination programs. Because older, nonvaccinated cohorts benefit only a little from HPV vaccination, ICC incidence in the total population will remain high as long as these cohorts still exist (29, 30). However, our estimates of remaining lifetime ICC risk apply to those vaccinated cohorts among which vaccine-protected HPV types have been eliminated. The first vaccinated cohorts will still experience the force of infection of vaccine-protected HPV types from the older, nonvaccinated cohorts (29–31),
but when the first vaccinated cohorts have passed the ages of highest sexual activity and there are sufficiently vaccinated cohorts between nonvaccinated cohorts and new vaccinated cohorts, incidence of HPV infection in the new vaccinated cohorts will be close to the new steady state (29–31). In contrast, every birth cohort that missed HPV vaccination because of delays in program introduction would eventually miss the estimated reduction of 500–600 ICC cases per 100,000 female births, depending on the vaccine used. The numbers would be even higher for a less frequently screened population.

Our results demonstrate the preventive potential of optimal high-coverage vaccination programs, beyond the vaccine efficacies. The effectiveness of vaccination program depends on viral characteristics of each HPV type (32). Mathematical models suggest that the effective coverage of vaccination (efficacy times coverage) might have to be greater than 70% for both boys and girls to eliminate HPV 16, but the requirement for the other types is considerably lower (10, 32). Even though the vaccine protection is generally lower for cross-protected types than for vaccine-targeted types, the suboptimal vaccine efficacy of cross-protection may be improved by herd effects with optimally organized vaccination programs (33).

The full public health impacts of HPV vaccination will not consist of prevented cancer cases only; benefits will also arise from reducing precancerous screening findings and from optimizing cervical cancer screening. The comprehensive age-specific and type-specific ICC incidences presented here will help with the development of mathematical models assessing these benefits.

We have presented quantified age-specific estimates of remaining cervical cancer incidence in the absence of vaccine-protected HPV types in a population which has been screened intensively for decades. The very low numbers of cervical cancer cases projected to exist after elimination of vaccine-protected HPV types reflect the high cancer-preventive potential of effective vaccination programs, even among reproductive-age women, who are currently experiencing a peak in age-specific cervical cancer incidence.

This study was supported by the Swedish Foundation for Strategic Research (grant KF10-0046), the Academy of Finland, the Nordic Academy for Advanced Studies, and Cancerfonden (the Swedish Cancer Society).

We thank Dr. Walter Ryd for histopathological review and Pouran Almstedt for data management.

J.D. has obtained grants to his institution from Roche Molecular Systems, Inc. (Pleasanton, California) and Genomica, S.A.U. (Madrid, Spain) for research on HPV tests. J.D., M.L., and K.S. have obtained grants to their institution for research on HPV vaccines from Merck & Co., Inc. (Kenilworth, New Jersey) and GlaxoSmithKline Pharmaceuticals SA/NV (Wavre, Belgium) (M.L. only), manufacturers of HPV vaccines. The other authors have no potential conflicts of interest to declare.

ACKNOWLEDGMENTS

Author affiliations: Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland (Simopekka Vänskä, Matti Lehtinen); Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden (Simopekka Vänskä, Tapio Luostarinen, Camilla Lagheden, Carina Eklund, Sara Nordqvist Kleppe, Karin Sundström, Matti Lehtinen, Joakim Dillner); Finnish Cancer Registry, Helsinki, Finland (Tapio Luostarinen); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Bengt Andrae, Pär Sparén); Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden (Karin Sundström, Joakim Dillner); and School of Health Sciences, Tampere University, Tampere, Finland (Matti Lehtinen).

REFERENCES

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19.
2. International Agency for Research on Cancer. Biological Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100B. Lyon, France: International Agency for Research on Cancer; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php. Accessed April 29, 2020.
3. Arbyn M, Castellsague X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–2686.
4. The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
5. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.
6. Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–2159.
7. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013;10(7):400–410.
8. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–789.
9. Lehtinen M, Luostarinen T, Vänskä S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: results of a community randomized trial (III). Int J Cancer. 2018;143(9):2299–2310.
10. Bisson M, Bénard E, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and
meta-analysis of predictions from transmission-dynamic models. *Lancet Public Health*. 2016;1(1):e8–e17.

11. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol*. 2010;11(11):1048–1056.

12. Bzhalava D, Guan P, Franceschi S, et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. *Virology*. 2013;445(1-2):224–231.

13. Hammer A, Rositch A, Qeadan F, et al. Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis. *Int J Cancer*. 2016;138(12):2795–2803.

14. Mesher D, Cuschieri K, Hibbitts S, et al. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. *J Clin Pathol*. 2015;68(2):135–140.

15. Lagheden C, Eklund C, Lamin H, et al. Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. *Br J Cancer*. 2018;118(10):1377–1381.

16. Steinau M, Patel SS, Unger ER. Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. *J Mol Diagn*. 2011;13(4):377–381.

17. Lagheden C, Eklund C, Kleppe SN, et al. Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. *J Clin Virol*. 2016;80:36–39.

18. Söderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. *J Clin Microbiol*. 2009;47(3):541–546.

19. Schmitt M, Bravo IG, Snijders PJ, et al. Bead-based multiplex genotyping of human papillomaviruses. *J Clin Microbiol*. 2006;44(2):504–512.

20. Statistics Sweden. Life table by sex and age. Year 1960–2019. 2019. http://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101I_LivslangdEttariga/. Accessed May 23, 2017.

21. Segi M, ed. *Cancer Mortality for Selected Sites in 24 Countries 1950–57*. Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.

22. Lehtinen M, Söderlund-Strand A, Vänskä S, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus—results of a community-randomized clinical trial (I). *Int J Cancer*. 2018;142(5):949–958.